SARS-CoV-2 mRNA vaccination induces an antigen-specific T cell response correlating with plasma interferon-gamma in B cell depleted patients
Emerging evidence is encouraging and suggests that a substantial proportion of patients without antibody responses (due to anti-CD20 therapy or other etiologies) to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines develop T cell responses. However, antigen-specific T cellular re...
Gespeichert in:
| Veröffentlicht in: | Journal of neuroimmunology 2023-10, Vol.383, p.578192-578192, Article 578192 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 578192 |
|---|---|
| container_issue | |
| container_start_page | 578192 |
| container_title | Journal of neuroimmunology |
| container_volume | 383 |
| creator | Borko, Tyler L. Baxter, Ryan Cabrera-Martinez, Berenice Thiruppathi, Eagappanath Sabalza, Maite Venkataraman, Iswariya Selva, Sean Rester, Cody Sillau, Stefan Pastula, Daniel M. Bennett, Jeffrey L. Alvarez, Enrique Gross, Robert Shah, Anna Kammeyer, Ryan Corboy, John R. Kedl, Ross M. Hsieh, Elena W.Y. Piquet, Amanda L. |
| description | Emerging evidence is encouraging and suggests that a substantial proportion of patients without antibody responses (due to anti-CD20 therapy or other etiologies) to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines develop T cell responses. However, antigen-specific T cellular responses are notoriously difficult to assess clinically, given the lack of such assays under satisfactory CAP/CLIA regulation, and the laborious nature of the flow cytometric assessment. To evaluate the ability to apply a clinically feasible assay to measure T cellular responses to SARS-CoV-2 mRNA vaccination, we compared flow cytometric and enzyme-linked immunosorbent assay (ELISA) based assays in 24 participants treated with anti-CD20 therapy. T cellular activation (CD69 + CD137+ surface expression, i.e., activation induced markers [AIM]) and intracellular interferon gamma (INFγ) production via flow cytometry was compared to plasma Interferon Gamma Release Assay (IGRA) via ELISA. Plasma INFγ production measured by IGRA correlated with the percent of INFγ-producing AIM positive T cells, supporting the use of IGRA assay as a robust assessment of T cellular response to the SARS-CoV-2 vaccine for B-cell depleted patients that is clinically feasible, time efficient, and cost effective.
[Display omitted] |
| doi_str_mv | 10.1016/j.jneuroim.2023.578192 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10863651</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165572823001789</els_id><sourcerecordid>2861304377</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-f8e351f984633f24c304fba6fef1c14a23a6cb5d138d44e2366fb31e64c29e613</originalsourceid><addsrcrecordid>eNqFkdtuFCEYx4mxsWv1FRouvZmV0zDsla4bT0lTk7Z6S1jmY8tmBkaYWeM7-NCyTtvUqyYkJPA_wPdD6JySJSVUvt0v9wGmFH2_ZITxZd0oumLP0IKqhlVKMPocLYqwruqGqVP0Muc9IbTmYvUCnfJGSkm4WqA_1-ur62oTf1QM91eXa3ww1vpgRh8D9qGdLGRsQlmj30Go8gDWO2_xDbbQdThBHmLIgG1MCbriCzv8y4-3eOhM7k3JGCE5SDFUO9P_O8AfZm8LQwcjtHgoNghjfoVOnOkyvL7bz9D3Tx9vNl-qi2-fv27WF5XlDR0rp4DX1K2UkJw7Jiwnwm2NdOCopcIwbqTd1i3lqhUCGJfSbTkFKSxbgaT8DL2bc4dp20NrS3cynR6S7036raPx-v-b4G_1Lh40JUpyWR8T3twlpPhzgjzq3ufjp0yAOGXNVKkhgjdNkcpZalPMOYF76KFEH1nqvb5nqY8s9cyyGM8fv_LBdg-vCN7PAiizOnhIOtsyRwutT2BH3Ub_VMdfeVS2iQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2861304377</pqid></control><display><type>article</type><title>SARS-CoV-2 mRNA vaccination induces an antigen-specific T cell response correlating with plasma interferon-gamma in B cell depleted patients</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Borko, Tyler L. ; Baxter, Ryan ; Cabrera-Martinez, Berenice ; Thiruppathi, Eagappanath ; Sabalza, Maite ; Venkataraman, Iswariya ; Selva, Sean ; Rester, Cody ; Sillau, Stefan ; Pastula, Daniel M. ; Bennett, Jeffrey L. ; Alvarez, Enrique ; Gross, Robert ; Shah, Anna ; Kammeyer, Ryan ; Corboy, John R. ; Kedl, Ross M. ; Hsieh, Elena W.Y. ; Piquet, Amanda L.</creator><creatorcontrib>Borko, Tyler L. ; Baxter, Ryan ; Cabrera-Martinez, Berenice ; Thiruppathi, Eagappanath ; Sabalza, Maite ; Venkataraman, Iswariya ; Selva, Sean ; Rester, Cody ; Sillau, Stefan ; Pastula, Daniel M. ; Bennett, Jeffrey L. ; Alvarez, Enrique ; Gross, Robert ; Shah, Anna ; Kammeyer, Ryan ; Corboy, John R. ; Kedl, Ross M. ; Hsieh, Elena W.Y. ; Piquet, Amanda L.</creatorcontrib><description>Emerging evidence is encouraging and suggests that a substantial proportion of patients without antibody responses (due to anti-CD20 therapy or other etiologies) to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines develop T cell responses. However, antigen-specific T cellular responses are notoriously difficult to assess clinically, given the lack of such assays under satisfactory CAP/CLIA regulation, and the laborious nature of the flow cytometric assessment. To evaluate the ability to apply a clinically feasible assay to measure T cellular responses to SARS-CoV-2 mRNA vaccination, we compared flow cytometric and enzyme-linked immunosorbent assay (ELISA) based assays in 24 participants treated with anti-CD20 therapy. T cellular activation (CD69 + CD137+ surface expression, i.e., activation induced markers [AIM]) and intracellular interferon gamma (INFγ) production via flow cytometry was compared to plasma Interferon Gamma Release Assay (IGRA) via ELISA. Plasma INFγ production measured by IGRA correlated with the percent of INFγ-producing AIM positive T cells, supporting the use of IGRA assay as a robust assessment of T cellular response to the SARS-CoV-2 vaccine for B-cell depleted patients that is clinically feasible, time efficient, and cost effective.
[Display omitted]</description><identifier>ISSN: 0165-5728</identifier><identifier>EISSN: 1872-8421</identifier><identifier>DOI: 10.1016/j.jneuroim.2023.578192</identifier><identifier>PMID: 37666038</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antibodies, Viral ; B-cell depletion ; B-Lymphocytes ; COVID ; COVID-19 - prevention & control ; COVID-19 Vaccines - immunology ; Humans ; Interferon-gamma - immunology ; Multiple sclerosis ; Ocrelizumab ; Rituximab ; SARS-CoV-2 ; T-Lymphocytes - immunology ; Vaccination</subject><ispartof>Journal of neuroimmunology, 2023-10, Vol.383, p.578192-578192, Article 578192</ispartof><rights>2023</rights><rights>Copyright © 2023. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c371t-f8e351f984633f24c304fba6fef1c14a23a6cb5d138d44e2366fb31e64c29e613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jneuroim.2023.578192$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37666038$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Borko, Tyler L.</creatorcontrib><creatorcontrib>Baxter, Ryan</creatorcontrib><creatorcontrib>Cabrera-Martinez, Berenice</creatorcontrib><creatorcontrib>Thiruppathi, Eagappanath</creatorcontrib><creatorcontrib>Sabalza, Maite</creatorcontrib><creatorcontrib>Venkataraman, Iswariya</creatorcontrib><creatorcontrib>Selva, Sean</creatorcontrib><creatorcontrib>Rester, Cody</creatorcontrib><creatorcontrib>Sillau, Stefan</creatorcontrib><creatorcontrib>Pastula, Daniel M.</creatorcontrib><creatorcontrib>Bennett, Jeffrey L.</creatorcontrib><creatorcontrib>Alvarez, Enrique</creatorcontrib><creatorcontrib>Gross, Robert</creatorcontrib><creatorcontrib>Shah, Anna</creatorcontrib><creatorcontrib>Kammeyer, Ryan</creatorcontrib><creatorcontrib>Corboy, John R.</creatorcontrib><creatorcontrib>Kedl, Ross M.</creatorcontrib><creatorcontrib>Hsieh, Elena W.Y.</creatorcontrib><creatorcontrib>Piquet, Amanda L.</creatorcontrib><title>SARS-CoV-2 mRNA vaccination induces an antigen-specific T cell response correlating with plasma interferon-gamma in B cell depleted patients</title><title>Journal of neuroimmunology</title><addtitle>J Neuroimmunol</addtitle><description>Emerging evidence is encouraging and suggests that a substantial proportion of patients without antibody responses (due to anti-CD20 therapy or other etiologies) to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines develop T cell responses. However, antigen-specific T cellular responses are notoriously difficult to assess clinically, given the lack of such assays under satisfactory CAP/CLIA regulation, and the laborious nature of the flow cytometric assessment. To evaluate the ability to apply a clinically feasible assay to measure T cellular responses to SARS-CoV-2 mRNA vaccination, we compared flow cytometric and enzyme-linked immunosorbent assay (ELISA) based assays in 24 participants treated with anti-CD20 therapy. T cellular activation (CD69 + CD137+ surface expression, i.e., activation induced markers [AIM]) and intracellular interferon gamma (INFγ) production via flow cytometry was compared to plasma Interferon Gamma Release Assay (IGRA) via ELISA. Plasma INFγ production measured by IGRA correlated with the percent of INFγ-producing AIM positive T cells, supporting the use of IGRA assay as a robust assessment of T cellular response to the SARS-CoV-2 vaccine for B-cell depleted patients that is clinically feasible, time efficient, and cost effective.
[Display omitted]</description><subject>Antibodies, Viral</subject><subject>B-cell depletion</subject><subject>B-Lymphocytes</subject><subject>COVID</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines - immunology</subject><subject>Humans</subject><subject>Interferon-gamma - immunology</subject><subject>Multiple sclerosis</subject><subject>Ocrelizumab</subject><subject>Rituximab</subject><subject>SARS-CoV-2</subject><subject>T-Lymphocytes - immunology</subject><subject>Vaccination</subject><issn>0165-5728</issn><issn>1872-8421</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkdtuFCEYx4mxsWv1FRouvZmV0zDsla4bT0lTk7Z6S1jmY8tmBkaYWeM7-NCyTtvUqyYkJPA_wPdD6JySJSVUvt0v9wGmFH2_ZITxZd0oumLP0IKqhlVKMPocLYqwruqGqVP0Muc9IbTmYvUCnfJGSkm4WqA_1-ur62oTf1QM91eXa3ww1vpgRh8D9qGdLGRsQlmj30Go8gDWO2_xDbbQdThBHmLIgG1MCbriCzv8y4-3eOhM7k3JGCE5SDFUO9P_O8AfZm8LQwcjtHgoNghjfoVOnOkyvL7bz9D3Tx9vNl-qi2-fv27WF5XlDR0rp4DX1K2UkJw7Jiwnwm2NdOCopcIwbqTd1i3lqhUCGJfSbTkFKSxbgaT8DL2bc4dp20NrS3cynR6S7036raPx-v-b4G_1Lh40JUpyWR8T3twlpPhzgjzq3ufjp0yAOGXNVKkhgjdNkcpZalPMOYF76KFEH1nqvb5nqY8s9cyyGM8fv_LBdg-vCN7PAiizOnhIOtsyRwutT2BH3Ub_VMdfeVS2iQ</recordid><startdate>20231015</startdate><enddate>20231015</enddate><creator>Borko, Tyler L.</creator><creator>Baxter, Ryan</creator><creator>Cabrera-Martinez, Berenice</creator><creator>Thiruppathi, Eagappanath</creator><creator>Sabalza, Maite</creator><creator>Venkataraman, Iswariya</creator><creator>Selva, Sean</creator><creator>Rester, Cody</creator><creator>Sillau, Stefan</creator><creator>Pastula, Daniel M.</creator><creator>Bennett, Jeffrey L.</creator><creator>Alvarez, Enrique</creator><creator>Gross, Robert</creator><creator>Shah, Anna</creator><creator>Kammeyer, Ryan</creator><creator>Corboy, John R.</creator><creator>Kedl, Ross M.</creator><creator>Hsieh, Elena W.Y.</creator><creator>Piquet, Amanda L.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20231015</creationdate><title>SARS-CoV-2 mRNA vaccination induces an antigen-specific T cell response correlating with plasma interferon-gamma in B cell depleted patients</title><author>Borko, Tyler L. ; Baxter, Ryan ; Cabrera-Martinez, Berenice ; Thiruppathi, Eagappanath ; Sabalza, Maite ; Venkataraman, Iswariya ; Selva, Sean ; Rester, Cody ; Sillau, Stefan ; Pastula, Daniel M. ; Bennett, Jeffrey L. ; Alvarez, Enrique ; Gross, Robert ; Shah, Anna ; Kammeyer, Ryan ; Corboy, John R. ; Kedl, Ross M. ; Hsieh, Elena W.Y. ; Piquet, Amanda L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-f8e351f984633f24c304fba6fef1c14a23a6cb5d138d44e2366fb31e64c29e613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies, Viral</topic><topic>B-cell depletion</topic><topic>B-Lymphocytes</topic><topic>COVID</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines - immunology</topic><topic>Humans</topic><topic>Interferon-gamma - immunology</topic><topic>Multiple sclerosis</topic><topic>Ocrelizumab</topic><topic>Rituximab</topic><topic>SARS-CoV-2</topic><topic>T-Lymphocytes - immunology</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borko, Tyler L.</creatorcontrib><creatorcontrib>Baxter, Ryan</creatorcontrib><creatorcontrib>Cabrera-Martinez, Berenice</creatorcontrib><creatorcontrib>Thiruppathi, Eagappanath</creatorcontrib><creatorcontrib>Sabalza, Maite</creatorcontrib><creatorcontrib>Venkataraman, Iswariya</creatorcontrib><creatorcontrib>Selva, Sean</creatorcontrib><creatorcontrib>Rester, Cody</creatorcontrib><creatorcontrib>Sillau, Stefan</creatorcontrib><creatorcontrib>Pastula, Daniel M.</creatorcontrib><creatorcontrib>Bennett, Jeffrey L.</creatorcontrib><creatorcontrib>Alvarez, Enrique</creatorcontrib><creatorcontrib>Gross, Robert</creatorcontrib><creatorcontrib>Shah, Anna</creatorcontrib><creatorcontrib>Kammeyer, Ryan</creatorcontrib><creatorcontrib>Corboy, John R.</creatorcontrib><creatorcontrib>Kedl, Ross M.</creatorcontrib><creatorcontrib>Hsieh, Elena W.Y.</creatorcontrib><creatorcontrib>Piquet, Amanda L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borko, Tyler L.</au><au>Baxter, Ryan</au><au>Cabrera-Martinez, Berenice</au><au>Thiruppathi, Eagappanath</au><au>Sabalza, Maite</au><au>Venkataraman, Iswariya</au><au>Selva, Sean</au><au>Rester, Cody</au><au>Sillau, Stefan</au><au>Pastula, Daniel M.</au><au>Bennett, Jeffrey L.</au><au>Alvarez, Enrique</au><au>Gross, Robert</au><au>Shah, Anna</au><au>Kammeyer, Ryan</au><au>Corboy, John R.</au><au>Kedl, Ross M.</au><au>Hsieh, Elena W.Y.</au><au>Piquet, Amanda L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SARS-CoV-2 mRNA vaccination induces an antigen-specific T cell response correlating with plasma interferon-gamma in B cell depleted patients</atitle><jtitle>Journal of neuroimmunology</jtitle><addtitle>J Neuroimmunol</addtitle><date>2023-10-15</date><risdate>2023</risdate><volume>383</volume><spage>578192</spage><epage>578192</epage><pages>578192-578192</pages><artnum>578192</artnum><issn>0165-5728</issn><eissn>1872-8421</eissn><abstract>Emerging evidence is encouraging and suggests that a substantial proportion of patients without antibody responses (due to anti-CD20 therapy or other etiologies) to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines develop T cell responses. However, antigen-specific T cellular responses are notoriously difficult to assess clinically, given the lack of such assays under satisfactory CAP/CLIA regulation, and the laborious nature of the flow cytometric assessment. To evaluate the ability to apply a clinically feasible assay to measure T cellular responses to SARS-CoV-2 mRNA vaccination, we compared flow cytometric and enzyme-linked immunosorbent assay (ELISA) based assays in 24 participants treated with anti-CD20 therapy. T cellular activation (CD69 + CD137+ surface expression, i.e., activation induced markers [AIM]) and intracellular interferon gamma (INFγ) production via flow cytometry was compared to plasma Interferon Gamma Release Assay (IGRA) via ELISA. Plasma INFγ production measured by IGRA correlated with the percent of INFγ-producing AIM positive T cells, supporting the use of IGRA assay as a robust assessment of T cellular response to the SARS-CoV-2 vaccine for B-cell depleted patients that is clinically feasible, time efficient, and cost effective.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>37666038</pmid><doi>10.1016/j.jneuroim.2023.578192</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-5728 |
| ispartof | Journal of neuroimmunology, 2023-10, Vol.383, p.578192-578192, Article 578192 |
| issn | 0165-5728 1872-8421 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10863651 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Antibodies, Viral B-cell depletion B-Lymphocytes COVID COVID-19 - prevention & control COVID-19 Vaccines - immunology Humans Interferon-gamma - immunology Multiple sclerosis Ocrelizumab Rituximab SARS-CoV-2 T-Lymphocytes - immunology Vaccination |
| title | SARS-CoV-2 mRNA vaccination induces an antigen-specific T cell response correlating with plasma interferon-gamma in B cell depleted patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T19%3A44%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SARS-CoV-2%20mRNA%20vaccination%20induces%20an%20antigen-specific%20T%20cell%20response%20correlating%20with%20plasma%20interferon-gamma%20in%20B%20cell%20depleted%20patients&rft.jtitle=Journal%20of%20neuroimmunology&rft.au=Borko,%20Tyler%20L.&rft.date=2023-10-15&rft.volume=383&rft.spage=578192&rft.epage=578192&rft.pages=578192-578192&rft.artnum=578192&rft.issn=0165-5728&rft.eissn=1872-8421&rft_id=info:doi/10.1016/j.jneuroim.2023.578192&rft_dat=%3Cproquest_pubme%3E2861304377%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2861304377&rft_id=info:pmid/37666038&rft_els_id=S0165572823001789&rfr_iscdi=true |